Literature DB >> 26948314

Involvement of opioid receptors in the systemic and peripheral antinociceptive actions of montelukast in the animal models of pain.

Behnam Ghorbanzadeh1, Mohammad Taghi Mansouri2, Hedayat Sahraei3, Soheila Alboghobeish4.   

Abstract

This study aimed to investigate the involvement of opioid receptors in the systemic and peripheral antinociceptive activities of montelukast in different animal models of pain. Rats and mice were injected with montelukast to produce analgesia. The formalin and acetic acid-induced writhing tests were used to assess the nociceptive activity. The results showed that i.p. administration of montelukast (0.3-10mg/kg) dose-dependently reduced flinching behavior in both the first and second phases of formalin test with mean ED50 of 0.55 and 5.31mg/kg, respectively. Also, intraplantar administration of montelukast (3-30μg/paw) produced antinociception against the two phases of formalin assay in a dose-dependent way with mean ED30 of 2.92 and 8.11μg/paw, respectively. Furthermore, pre-treatment with naloxone (a non-selective opioid receptor antagonist) significantly inhibited both the systemic and also peripheral antinociceptive actions of montelukast in formalin test. In writhing test, the results showed that intraperitoneal administration of montelukast (3-10mg/kg) significantly reduced the writhe number induced by acetic acid in mice. Moreover, co-administration of non-effective doses of montelukast (0.3 and 1mg/kg; i.p.) and morphine (0.25mg/kg; i.p.) significantly decreased the writhes number induced by acetic acid. Also, this effect was naloxone-reversible. These findings suggest that the systemic and peripheral antinociception produced by montelukast were mediated through the opioid receptors in central and peripheral nervous systems. Moreover, combination of montelukast and morphine could be noted as a new strategy for pain relief.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antinociception; Formalin test; Montelukast; Opioid receptors; Potentiation; Wrighting

Mesh:

Substances:

Year:  2016        PMID: 26948314     DOI: 10.1016/j.ejphar.2016.03.010

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Montelukast suppresses the development of irritable bowel syndrome phenotype possibly through modulating NF-κB signaling in an experimental model.

Authors:  Pariya Khodabakhsh; Nilgoon Khoie; Ahmad-Reza Dehpour; Alireza Abdollahi; Mahmoud Ghazi-Khansari; Hamed Shafaroodi
Journal:  Inflammopharmacology       Date:  2022-01-10       Impact factor: 4.473

2.  The effect of montelukast, a leukotriene receptor antagonist, on the acetic acid-induced model of colitis in rats: Involvement of NO-cGMP-KATP channels pathway.

Authors:  Behnam Ghorbanzadeh; Mohammad Amin Behmanesh; Roya Mahmoudinejad; Mehdi Zamaniyan; Shadi Ekhtiar; Yousef Paridar
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

3.  Identifying FAAH Inhibitors as New Therapeutic Options for the Treatment of Chronic Pain through Drug Repurposing.

Authors:  Anca Zanfirescu; Georgiana Nitulescu; Dragos Paul Mihai; George Mihai Nitulescu
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.